Translate Bio, Inc., a messenger RNA therapeutics company, engages in developing medicines to treat diseases caused by protein or gene dysfunction. It is developing MRT5005 that is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 for the treatment of ornithine transcarbamylase deficiency. It has strategic alliances with Sanofi Pasteur. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. was founded in 2011 and is headquartered in Lexington, Massachusetts.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone617-945-7361
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date3/21/2019 (Estimated)
OptionableNot Optionable
Translate Bio (NASDAQ:TBIO) Frequently Asked Questions
What is Translate Bio's stock symbol?
Translate Bio trades on the NASDAQ under the ticker symbol "TBIO."
How were Translate Bio's earnings last quarter?
Translate Bio Inc (NASDAQ:TBIO) released its quarterly earnings results on Thursday, August, 9th. The company reported ($2.94) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.70 by $3.64. View Translate Bio's Earnings History.
When is Translate Bio's next earnings date?
What price target have analysts set for TBIO?
4 equities research analysts have issued 12 month price objectives for Translate Bio's shares. Their forecasts range from $20.00 to $25.00. On average, they anticipate Translate Bio's stock price to reach $22.75 in the next year. This suggests a possible upside of 138.5% from the stock's current price. View Analyst Price Targets for Translate Bio.
What is the consensus analysts' recommendation for Translate Bio?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Translate Bio in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Translate Bio.
Has Translate Bio been receiving favorable news coverage?
Media coverage about TBIO stock has been trending somewhat positive this week, according to InfoTrie. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Translate Bio earned a news impact score of 1.7 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the immediate future.
Who are some of Translate Bio's key competitors?
Some companies that are related to Translate Bio include Audentes Therapeutics (BOLD), Momenta Pharmaceuticals (MNTA), Orchard Therapeutics (ORTX), Alector (ALEC), Rubius Therapeutics (RUBY), Iovance Biotherapeutics (IOVA), Editas Medicine (EDIT), Fate Therapeutics (FATE), Coherus Biosciences (CHRS), Autolus Therapeutics (AUTL), Sangamo Therapeutics (SGMO), BioCryst Pharmaceuticals (BCRX), Vericel (VCEL), Cellectis (CLLS) and NanoString Technologies (NSTG).
What other stocks do shareholders of Translate Bio own?
Who are Translate Bio's key executives?
Translate Bio's management team includes the folowing people:
- Mr. Ronald C. Renaud Jr., Pres, CEO & Director (Age 50)
- Dr. Michael W. Heartlein, Chief Scientific Officer & CTO (Age 60)
- Mr. John R. Schroer CFA, CFO & Treasurer (Age 54)
- Mr. Paul D. Burgess J.D., Gen. Counsel (Age 46)
- Ms. Paula A. Cloghessy, Sr. VP of Human Resource (Age 48)
When did Translate Bio IPO?
(TBIO) raised $100 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 7,700,000 shares at a price of $12.00-$14.00 per share. Citigroup, Leerink Partners and Evercore ISI acted as the underwriters for the IPO.
Who are Translate Bio's major shareholders?
Translate Bio's stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (15.00%), Atlas Venture Advisors Inc. (8.69%), BlackRock Inc. (2.18%), Perceptive Advisors LLC (0.96%), Sphera Funds Management LTD. (0.69%) and Geode Capital Management LLC (0.26%). Company insiders that own Translate Bio stock include Brian M Jr Gallagher and Mrl Ventures Fund Llc. View Institutional Ownership Trends for Translate Bio.
Which institutional investors are selling Translate Bio stock?
Which institutional investors are buying Translate Bio stock?
TBIO stock was acquired by a variety of institutional investors in the last quarter, including Atlas Venture Advisors Inc., BlackRock Inc., FMR LLC, Fosun International Ltd, Geode Capital Management LLC, Geode Capital Management LLC, Norges Bank and Sphera Funds Management LTD.. Company insiders that have bought Translate Bio stock in the last two years include Brian M Jr Gallagher and Mrl Ventures Fund Llc. View Insider Buying and Selling for Translate Bio.
How do I buy shares of Translate Bio?
Shares of TBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Translate Bio's stock price today?
One share of TBIO stock can currently be purchased for approximately $9.54.
How big of a company is Translate Bio?
Translate Bio has a market capitalization of $430.64 million.
What is Translate Bio's official website?
How can I contact Translate Bio?
Translate Bio's mailing address is 29 HARTWELL AVENUE, LEXINGTON MA, 02421. The company can be reached via phone at 617-945-7361.
MarketBeat Community Rating for Translate Bio (NASDAQ TBIO)
MarketBeat's community ratings are surveys of what our community members think about Translate Bio and other stocks. Vote "Outperform" if you believe TBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TBIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
